# The Use of Midazolam and Remifentanil During Dialysis Access Procedures

> **NCT04226443** · NA · COMPLETED · sponsor: **Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital** · enrollment: 99 (actual)

## Conditions studied

- Sedative Adverse Reaction
- Analgesic Adverse Reaction
- Midazolam Adverse Reaction
- Adverse Reaction to Drug
- Patient Satisfaction
- Chronic Kidney Diseases
- Arteriovenous Fistula

## Interventions

- **DRUG:** Midazolam intravenous injection
- **DRUG:** Remifentanil intravenous bolus dose

## Key facts

- **NCT ID:** NCT04226443
- **Lead sponsor:** Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-28
- **Primary completion:** 2016-04-15
- **Final completion:** 2016-04-30
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226443, "The Use of Midazolam and Remifentanil During Dialysis Access Procedures". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04226443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*